NEW YORK , Nov. 15, 2024 /PRNewswire/ -- Report on how AI is driving market transformation - The global regenerative medicine market size is estimated to grow by USD 70.11 billion from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of over 23.31% during the forecast period. Increasing prevalence of chronic diseases is driving market growth, with a trend towards increasing number of clinical trials.
However, uncertain regulatory approval for regenerative medicine products poses a challenge.Key market players include AbbVie Inc., Amgen Inc.
, Baxter International Inc., Becton Dickinson and Co., Cook Group Inc.
, F. Hoffmann La Roche Ltd., Gilead Sciences Inc.
, Integra Lifesciences Corp., Johnson and Johnson, Medtronic Plc, Merck and Co. Inc.
, Mesoblast Ltd., MiMedx Group Inc., Novartis AG, Nuvasive Inc.
, Organogenesis Holdings Inc., Smith and Nephew plc, Thermo Fisher Scientific Inc., Vericel Corp.
, and Zimmer Biomet Holdings Inc.. AI-Powered Market Evolution Insights.
Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View Free Sample Report PDF Key Market Trends Fueling Growth The Regenerative Medicine market is experiencing significant growth due to the increasing focus on treating complex conditions such as blood cancers and rare diseases. Personalized medicine, gene therapy, and CRISPR technology are key trends driving this growth. Companies like Metcela Inc and Integra LifeSciences are lea.